SKIN The Journal of Cutaneous Medicine

Dr. Divija Sharma, Caroline Silver, Dr. Camille Powers, Dr. Ross O'Hagan, Chelsea Stephens, Dr. Maria Lira Paula Mendoza, Jasmine Levine, Dr. Ahuva Cices, Dr. Nicholas Gulati, Dr. Benjamin Ungar

Page 3007 - 3011

PDF KOL SUMMARY

Brief Articles

Gamer’s Dermatitis: When Victory Comes with a Rash

Aidan Maxwell, Madison Anzelc, Dawn Merritt

Page 3012 - 3016

PDF

A Rare Case of Superficial CD34+ Fibroblastic Tumor: A Case Report

Luke Hamilton, Antonio Jimenez, Anthony Linfante

Page 3017 - 3021

PDF

Development and Resolution of Cutaneous Lupus Erythematosus During Long-Term Pexidartinib Therapy

Robyn G. Ku, Khushnood Faraz, Kasey McCollum, Rami Al-Rohil, Anne Marano

Page 3022 - 3026

PDF

A 14-year-old Girl with Atrophic Plaques on the Arm: Case Report

Hannah R. Riva, MD, Mary E. Cavanagh, MD, Ayezel Munoz Gonzalez, MD

Page 3027 - 3031

PDF

Dermatologic Presentation of Etanercept-Induced Lupus in Rheumatoid Arthritis

Salma Bennis, Emily Deehan, Joseph Gofman, Mathew Farbman

Page 3032 - 3039

PDF

A Unique Case of Heat-Induced Livedo Reticularis Following Initiation of Upadacitinib

Anya Patel, Kateryna Karpoff, Mark Lebwohl

Page 3040-3042

PDF

A Case of Lichenoid Drug Eruption Following Risankizumab Therapy

Zachary Levy, Sarah Romanelli Romanelli, Gretchen D. Ball, Stephen A. Switlyk, Alice B. Gottlieb

Page 3043-3047

PDF

Eruptive Cutaneous Metastatic Leiomyosarcoma

Tara McCaffrey, Dr. Raghav Tripathi, Dr. Rachel Marchalik, Dr. Grant Anhalt, Dr. Julie S. Deutsch, Dr. Anna Lien-Lun Chien

Page 3048-3053

PDF

Psoriasiform Lesions of Secondary Syphilis on the Trunk

Claudia Lasalle, Allison Kirchner, J. Thomas Landers

Page 3054 - 3057

PDF

Short Communications

Eye Movement Desensitization and Reprocessing (EMDR) Applications in Dermatology: A Call for Future Research

Sheila Sharifi, Isabella Tan, Mohammad Jafferany

Page 3067-3069

PDF

SKINmages: Clinical Images in Dermatology

Atypical Presentation of Calciphylaxis in an African American Male with End-Stage Renal Disease

Bhumik Patel, Dr. Cynthia Kuttner, Dr. Elizabeth T. N. Phung

Page 3058 - 3060

PDF

An Elusive Case of Cutaneous Leishmaniasis

Twan Sia, Jodi Y. So, Jennifer E. Yeh

Page 3061 - 3063

PDF

The Off-Label Use of Isotretinoin for Treatment of Rhinophyma

Nicole Chin, Robert S. Chin, Andrea H. Austin

Page 3064-3066

PDF

Compelling Comments

DIBO and DIVO: The Role of Acronyms in Mohs Micrographic Surgery for Efficient Dual-Headed Microscope Communication and Education

Alexa DiNello, BS, Hayden Smith, MD, Travis Blalock, MD, FAAD, FACMS, Jordan Lim, MB BCh BAO, FAAD, AACMS

Page 3070-3071

PDF

Poster Presentations at 2026 Winter Clinical Dermatology Conference®: Atopic Dermatitis

The Role and Risks of Systemic Corticosteroids in Atopic Dermatitis: An Expert Consensus

Joshua Burshtein, Christopher G. Bunick, Ruth Ann Vleugels, April W. Armstrong, Alexandra Golant, Todd Schlesinger, Bruce E. Strober, Eingun James Song, Linda Stein Gold, Milaan Shah, Lauren DeBusk, Angela Rosenberg, Brooke Bartley, Danny Zakria, Mark Lebwohl

Page s724

PDF

Tralokinumab versus Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis with Hand Involvement: a Matching-Adjusted Indirect Comparison

April Armstrong, Leon Kircik, Andrei Metelitsa, Richard B Warren, Adrian Rodriguez, Sebastian Volc, Naiem Issa, Raj Chovatiya, Rie von Eyben, Teodora Festini, Pierre Johansen, Benjamin Ehst

Page s725

PDF

Tralokinumab Significantly Reduces Work Productivity Impairment and Daily Activity Impairment in Adults With Atopic Dermatitis and Moderate-to-Severe Hand Involvement

Benjamin Ehst, Leon Kircik, Andrei Metelitsa, Sebastian Volc, Sonja Molin, Pierre Johansen, Farzaneh Safavimanesh, Ann-Marie Tindberg, April Armstrong

Page s726

PDF

Long-term Upadacitinib Safety in Moderate-to-Severe Atopic Dermatitis up to 7 Years: an Integrated Analysis with Over 9600 Patient-Years of exposure

Emma Guttman, Gweneth F Levy, Diego Ruiz DaSilva, Mona Shahriari, Linda Stein Gold, Nina Magnolo, Koji Masuda, Audrey Nosbaum, Peter Foley, Marni Wiseman, Ayman Grada, Yolanda Armendariz, Deanne M. Dilley, Alena Pechonkina, Christopher G. Bunick

Page s727

PDF

Real-World Effectiveness of Up to 12-Month Tralokinumab Treatment in Adults With Atopic Dermatitis Who Previously Discontinued Dupilumab or Janus Kinase Inhibitors

April Armstrong, Adrian Rodriguez, Jose Juan Pereyra Rodriguez, Ahmed Ameen, Elena Pezzolo, Jennifer Beecker, Teodora Festini, Frank Vinther, Ida Vittrup, Diamant Thaçi

Page s728

PDF

Real-World Safety and Effectiveness of Up to 12 Months of Tralokinumab Treatment in Adults With Atopic Dermatitis Who Discontinued Dupilumab Due to Conjunctivitis

April Armstrong, Cory Rubin, Silvia Ferruci, Pierre-Andre Becherel, Jose Juan Pereyra Rodriguez, Marni C Wiseman, Ahmed Ameen, Teodora Festini, Frank Vinther, Ida Vittrup, Diamant Thaçi

Page s729

PDF

Safety and Adverse Events of Special Interest in 825 Adults With Atopic Dermatitis Receiving Up to 12 Months of Tralokinumab Treatment in a Real-World Setting

Cory Rubin, Abel Jarell, Pierre-Andre Becherel, Elena Pezzolo, Fatima Albreiki, Tien Nguyen, Teodora Festini, Frank Vinther, Ida Vittrup, Diamant Thaçi

Page s730

PDF

Reduced Dosing Frequency With Tralokinumab Provides Sustained Improvements in Symptoms and Quality of Life Up to 1 Year in Adults With Moderate-to-Severe AD

April Armstrong, Leon Kircik, Ketty Peris, Melinda Gooderham, Sebastien Barbarot, Aleksandra Lesiak, Rie von Eyben, Niels Højsager Bennike, Ann-Marie Tindberg, Margitta Worm

Page s731

PDF

Sustained On- and Off-Treatment Disease Control in Patients With Moderate-to-Severe Atopic Dermatitis Following 12-Week, Open-Label, Once-Daily Abrocitinib 200 mg: A Post Hoc Analysis of the Phase 3 JADE REGIMEN Study

Emma Guttman-Yassky, Thomas Bieber, Jan Gutermuth, Kenji Kabashima, Stephan Weidinger, Andreas Wollenberg, Irina Lazariciu, Gerardo Encinas, Marina Mikheil, Melissa Watkins

Page s732

PDF

Efficacy and Safety of Abrocitinib Versus Dupilumab in Patients Who Self-Identified as Having Skin of Color: A Post Hoc Analysis of JADE COMPARE

Andrew Alexis, Meera R. Gupta, Kenji Kabashima, Fang Wang, Roger A. Edwards, Gianluca Bonfanti, Andrew Selfridge, Pinaki Biswas, Brian Esparza, Melissa Watkins

Page s733

PDF

Baseline Characteristics in Patients with Atopic Dermatitis from the North American Prospective Observational Study of Lebrikizumab (ADjoy)

Jennifer Soung, Vimal H. Prajapat, Jill Waibel, Lara Wine Lee, Lawrence F. Eichenfield , Abel Jarell, Alexa Hetzel, Gaia Gallo, Evangeline Pierce, Roberto Marrero, Amy Larkin, Michael Behling, Shawn Kwatra

Page s734

PDF

Rapid Itch Relief with Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Results from the Phase 3b/4 Level Up Study

Christopher G Bunick, Shawn Gaurav Kwatra, Hermenio Lima, Masatoshi Abe, Eingun James Song, Nadia Ibrahim, Cristina Sancho Sanchez, Namita Vigna, Michael Lane, Brian M Calimlim, Sonja Ständer

Page s735

PDF

Dupilumab Reduces Caregiver Burden and Family Impact Among Caregivers of Pediatric Patients With Moderate-to-Severe Atopic Dermatitis in Clinical Practice: RELIEVE-AD-PED Study

Dr. Amy S. Paller, Dr. April Armstrong, Dr. Zhixiao Wang, Dr. Kerry Noonan, Dr. Min Yang, Dr. Chien-Chia Chuang, Dr. Su Zhang, Dr. Debra Sierka, Dr. Brad Shumel, Dr. Jingdong Chao, Dr. Dimittri Delevry

Page s736

PDF

Dupilumab Improves Symptoms and Quality of Life in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis in Clinical Practice: RELIEVE-AD-PED Study

Dr. April Armstrong, Dr. Amy S. Paller, Dr. Zhixiao Wang, Dr. Kerry Noonan, Dr. Min Yang, Dr. Chien-Chia Chuang, Dr. Cheryl Xiang, Dr. Debra Sierka, Dr. Brad Shumel, Dr. Jingdong Chao, Dr. Dimittri Delevry

Page s737

PDF

Dupilumab Demonstrates a Significantly Higher Likelihood of Achieving Improvements in Atopic Dermatitis Signs and Itch vs Nemolizumab at Week 16 in Combination With Topical Corticosteroids: Results From a Bucher Placebo-Adjusted Indirect Comparison

Dr. Martin Steinhoff, Dr. DirkJan Hijnen, Dr. Vimal H. Prajapati, Dr. Jensen Yeung, Dr. Patricia Guyot, Dr. Yann Cabon, Dr. Yingxin Xu, Dr. Zhixiao Wang, Dr. Kerry Noonan, Dr. Mike Bastian

Page s738

PDF

Time to Efficacy Outcomes Among Biologic-Naive and -Exposed Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE REAL

Melinda J. Gooderham, Raj Chovatiya, Stephan Weidinger, Zhao Zuotao, Yukari Okubo, Irina Lazariciu, Herwig Koppensteiner, Carmen Tsang, Simon Chen

Page s739

PDF

Head and Neck Atopic Dermatitis: Therapeutic Response After Switching to Upadacitinib in Moderate-to-Severe Atopic Dermatitis Patients Who Had Inadequate Response to Dupilumab

Diego Ruiz Dasilva, Mona Shahriari, Masatoshi Abe, Tiago Torres, Simone Ribero, Henry Yu, Lauren Miller, Kathy Altman, Michael Lane, Alvaro A. Moreira, Ayman Grada, Christopher G. Bunick

Page s740

PDF

Rapid and Durable Skin Pain Relief with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Christopher G. Bunick, Peter A. Lio, Mona Shahriari, Diego Ruiz Dasilva, Ayman Grada, Brian Calimlim, David Prefontaine, Chao Li, Jianzhong Zhang, Vipul Jain, Pedro Mendes-Bastos, Eric L. Simpson

Page s741

PDF

Effect of Upadacitinib on Biomarkers of Systemic Inflammation in Patients with Moderate-to-Severe Atopic Dermatitis

Christopher G. Bunick, Shawn G. Kwatra, Ayman Grada, Yingtao Bi, James Fann, Sara Murdock, Emma Guttman-Yassky

Page s742

PDF

Impact of Achieving and Maintaining Minimal Disease Activity on Long-Term Patient-Reported Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Post-hoc Analysis from Measure Up 1 and 2

Tiago Torres, Vimal H. Prajapati, Laura Savage, Masatoshi Abe, Simone Ribero, Richard Ta, Chao Li, Ayman Grada, Meerat Oza, Wan-Ju Lee, Christopher G. Bunick

Page s743

PDF

Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-week Phase 3b ADHAND Trial

Benjamin Ehst, Richard B Warren, H. Chih-ho Hong, Dong Hun Lee, Andrei Metelitsa, Sebastian Volc, Marie Tauber, Farzaneh Safavimanesh, Ann-Marie Tindberg, Linda Stein Gold

Page s744

PDF

Once-daily Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Patients Aged 2–5 Years With Diverse Skin Types: Subgroup Analysis From the Phase 3 INTEGUMENT-PED Trial

Vimal H Prajapati, Lawrence F Eichenfield, John C Browning, Mercedes E Gonzalez, H Chih-ho Hong, Melissa S Seal, David Krupa, David R Berk, Robert C Higham, Patrick Burnett

Page s745

PDF

Real-World Effectiveness and Safety of Nemolizumab in Moderate-to-Severe Atopic Dermatitis: A Phase IV, Prospective, Non-Interventional Study Design From RE-UNITE-AD (NCT06988605)

Jonathan Silverberg, Martin Metz, Andrew Pink, Gil Yosipovitch, Carolyn Jack, Matteo Rossini, Liliana Ulianov, Rajesh Rout

Page s746

PDF

Real World Assessment of Once-a-Month Dosing of Lebrikizumab in Commercial Claims

Raj Chovatiya, William McCann, Lakshi Aldredge, Ray Gou, Josephine Tran, Alexandra Wallem, Evangeline Pierce, Louise Ann DeLuca-Carter, Shivani Pandya, Chen Chi-Chang, April Armstrong

Page s747

PDF

Cutaneous Safety Profile of Nemolizumab in Moderate‑to‑Severe Atopic Dermatitis and Prurigo Nodularis: Pooled Analysis of Phase 3 Trials (ARCADIA 1&2 and OLYMPIA 1&2) Nodularis: Pooled Analysis of Phase 3 Trials (ARCADIA 1&2 and OLYMPIA 1&2)

Curdin Conrad, Franz J. Legat, Sarina B. Elmariah, Martin Metz, Maxwell Sauder, Andrew E. Pink, Laurent Misery, Linda Stein-Gold, Raja K. Sivamani, Agnes Drahos, Zarif Jabbar-Lopez, Xiaoxiao Chen, Christophe Piketty, Rajesh Rout, Sonja Ständer, Aliene Noda

Page s748

PDF

Alopecia

Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata

Bianca Piraccini, Jennifer Soung, Thierry Passeron, Wenyu Wu, Misaki Kinoshita-Ise, Mercedes E. Gonzalez, GSH Ramakanth, Amita Priya Dommalapaty, Dalia Ballas Wajsbrot, Helen Tran, Monica Lindsay, Robert Wolk

Page s768

PDF

Acne & Rosacea

Efficacy and Safety of Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1%Compared With Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Participants With Moderate to Severe Acne

Zoe D. Draelos, Hilary Baldwin, Neal Bhatia, Lawrence F. Eichenfield, Karol Wroblewski, Dawn Z. Eichenfield, Leon H. Kircik

Page s764

PDF

Efficacy of Oral DFD-29, a Low-Dose Minocycline Formulation, in Patients in Germany and Patients in the US: An Analysis of Two Phase 3 Trials

Zoe Draelos, MD, Janet DuBois, MD, Oliver Weirich, MD, Shraddha Bayar, PharmD, Srinivas Sidgiddi, MD

Page s765

PDF

Psoriasis

Bimekizumab Safety in Patients with Psoriasis Achieving Complete Skin Clearance: 4-year Analysis from 5 Phase 3/3b Trials

Diamant Thaçi, Kenneth B. Gordon, Richard G. Langley, Andrew Blauvelt, Mari Higashiyama, Denis Jullien, Katy White, Susanne Wiegratz, Delphine Deherder, Nancy Cross, Mark Lebwohl

Page s757

PDF

Bimekizumab Remission and High Disease Control Over 4 years in Patients with Psoriasis Achieving Complete Skin Clearance at Week 16: Results from Four Phase 3 Trials

Richard B. Warren, Bruce Strober, Denis Jullien, Mark Lebwohl, Kilian Eyerich, Richard G. Langley, Balint Szilagyi, Rhys Warham, April Armstrong

Page s758

PDF

Real-World Insights Into First-Line Use of Topical Roflumilast Cream for Psoriasis

Raj Chovatiya, Jennifer Soung, Jennifer C Jaworski, Melissa S Seal, Diane Hanna, Brett Stephenson

Page s759

PDF

Pyoderma Gangrenosum

The Emotional Impact of Pyoderma Gangrenosum (PG): Real-world Experience of the PG Patient Journey

Alfsaneh Alavi, David De Pottie, Valentina Dini, Robert S. Kirsner, Juan Semeco, Alex G. Ortega-Loayza

Page s770

PDF

Skin Cancer

The 31-Gene Expression Profile Test Identifies Patients with AJCC T1a (<0.8mm) Cutaneous Melanoma at Increased Risk of 5-year Melanoma-Specific Mortality

Harrison Nguyen, MD, MBA, MPH, FAAD, Matthew S. Goldberg, MD, Mark Gimbel, MD, Jane Yoo, MD, Abel Jarell, MD, Eric Whitman, MD

Page s754

PDF

Intralesional Cemiplimab for Patients With Early-Stage Cutaneous Squamous Cell Carcinoma: Results From a Phase 1 Pilot Study Expansion Cohort

Michael Migden, Sherrif Ibrahim, John Strasswimmer, Nathalie Zeitouni, Gary S. Rogers, Jennifer DeSimone, Meenal Kheterpal, Hyunsil Han, Suk-Young Yoo, Mia Bao, Frank Seebach, Israel Lowy, Mihaela Cristea, Matthew Fury

Page s755

PDF

CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A Prospective, Non-Interventional Study of the Safety and Effectiveness of Cemiplimab in Immunocompromised/Immunosuppressed Patients With Advanced Cutaneous Squamous Cell Carcinoma at 2 Years’ Follow-Up

Soo J. Park, Guilherme Rabinowits, Michael J. Kelley, Emily S. Ruiz, Francis Worden, Cong Zhu, Debra A. G. McIntyre, Ruben G. W. Quek, Joy Wang, Karen Tumaneng, Sarah Nia, Jean-Francois Pouliot

Page s756

PDF

Hidradenitis Suppurativa

Bimekizumab Efficacy and Safety Through 3 Years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II Trials and Their Open-Label Extension BE HEARD EXT

John R. Ingram, Alexa B. Kimball, Amit Garg, Falk G. Bechara, Brian Kirby, Akimichi Morita, Wayne Gulliver, Bartosz Lukowski, Delphine Deherder, Jérémy Lambert, Christina Crater, Tom Vaux, Christopher J. Sayed

Page s762

PDF

Bimekizumab Improves HSSQ Skin Pain over 3 Years in HS: Data from BE HEARD EXT

Hadar Lev-Tov, Lauren A.V. Orenstein, Vivian Y. Shi, John R. Ingram, Hessel H. van der Zee, John W. Frew, Hideki Fujita, Christina Crater, Jérémy Lambert, Tae Oh, Nicola Tilt, Jacek C. Szepietowski

Page s763

PDF

Dermatopharmacology

Risk of Systemic Adverse Effects From Topical and Oral Corticosteroids: Time for a Paradigm Shift?

Alexandra Golant, Adam Friedman, Angela Lamb, Peter A Young, Douglas DiRuggiero, Melodie Young, Sally Laden, Jennifer C Jaworski, Krista Bohnert, Melissa S Seal, Diane Hanna

Page s771

PDF

Vitiligo

Understanding Work-related Economic Burden Among Adults with Vitiligo in the United States and Europe

Martine Maculaitis, Samantha K. Kurosky, Soohyun Hwang, Mojgan M. Sadrarhami, Nathaniel Way, Roni Adiri, Neelanzana Paudel, Pearl Craig, Genevieve Gauthier, Anna Dumas, Yousaf Aftab, Kristen King-Concialdi , Juliana M. Canosa, Elizabeth McCaig, Viktoria Eleftheriadou, Khaled Ezzedine

Page s749

PDF

Perceived and Enacted Stigma and the Association with Clinical Characteristics, Work Productivity, Activity Impairment, and Indirect Costs in Adults with Vitiligo in the United States and Europe

Soohyun Hwang, Nathaniel Way, Martine Maculaitis, Samantha K. Kurosky, Pearl Craig, Mojgan Sadrarhami, Roni Adiri, Kristen King-Concialdi, Elizabeth McCaig, Neelanzana Paudel, Genevieve Gauthier, Anna Dumas, Yousaf Aftab, Juliana M. Canosa, Viktoria Eleftheriadou, Khaled Ezzedine

Page s750

PDF

The Invisible Burden of a Visible Disease: Exploring Psychosocial Burden and Quality of Life Impairment in Vitiligo

Pearl Craig, Soohyun Hwang, Martine Maculaitis, Nathaniel Way, Samantha K. Kurosky, Neelanzana Paudel, Mojgan Sadrarhami, Anna Dumas, Roni Adiri, Kristen King-Concialdi, Elizabeth McCaig, Genevieve Gauthier, Yousaf Aftab, Juliana M. Canosa, Viktoria Eleftheriadou, Khaled Ezzedine

Page s751

PDF

Characterizing Deep Quality-of-Life Response in the TRuE-V1/TRuE-V2 Studies of Ruxolitinib Cream in Nonsegmental Vitiligo

Seemal R. Desai, Thierry Passeron, Pearl Grimes , Khaled Ezzedine, John E. Harris, Amy J. McMichael, Dan Sturm, Xavier Diaz, Haobo Ren, David Rosmarin

Page s752

PDF

Quality-of-Life Outcomes Among Patients Achieving High-Threshold Facial or Total Body Repigmentation With Ruxolitinib Cream in Nonsegmental Vitiligo

Seemal R. Desai, Thierry Passeron, Pearl Grimes, Khaled Ezzedine, John E. Harris, Amy J. McMichael, Dan Sturm, Xavier Diaz, Haobo Ren, David Rosmarin

Page s753

PDF

Pruritus & Prurigo Nodularis

Reduction in Pruritus Across Indications in Phase 3 Trials of Topical Roflumilast in Patients as Young as 2 Years

Gil Yosipovitch, Shawn G Kwatra, James Del Rosso, Laura K Ferris, Melinda Gooderham, Adelaide A Hebert, Edward Lain, Mark Lebwohl, Vimal H Prajapati, Todd Schlesinger, Jennifer Soung, Melissa S Seal, David Krupa, Robert C Higham, David R Berk, Patrick Burnett

Page s766

PDF

The RE-UNITE-PN Study Design – A Prospective, Non-Interventional, Phase 4 Study of Nemolizumab for the Treatment of Prurigo Nodularis

Shawn G. Kwatra, Sonja Ständer, Sarina B. Elmariah, Andrew E. Pink, Jacek C. Szepietowski, Matteo Rossini, Zarif Jabbar-Lopez, Rajesh Rout

Page s767

PDF

Lupus

Cutaneous Lupus Activity Investigator’s Global Assessment–Revised (CLA-IGA-R) Content Validity: Cutaneous Lupus Erythematosus (CLE) Patient Qualitative Study

Dr Joseph F Merola, MD, MMSc, Dr Weihong Yang, MD, PhD, Dr Qianyun Li, PhD, Dr Helen Doll, PhD, Dr Jason Randall, PhD, Dr Catherine Barbey, PhD, Dr Feng Zeng, PhD

Page s760

PDF

All Subcomponents of the Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) are Relevant to Identify and Detect Changes in Skin Activity

Dr Victoria P Werth, MD, Dr Joseph F Merola, MD, MMSc, Dr Qianyun Li, PhD, Dr Weihong Yang, MD, PhD, Dr Catherine Barbey, PhD

Page s761

PDF

Onychomycosis

Efficacy and Safety of Topical Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Trials by Race

Shari Lipner, Aditya K. Gupta, Tracey C. Vlahovic, Ted Rosen, Boni Elewski, Su Yong Choi, Linda Stein Gold

Page s769

PDF